Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 4Tumor-Agnostic 3Thoracic 3Sarcoma 3Other solid neoplasm 3CNS 3Breast 3Plasma cell 2Other hematologic neoplasm 2Myeloid 2Gastrointestinal 2Endocrine 2Dermatologic 2NET 1Lymphoid 1Gynecologic 1Classical hematology 1

Conditions

Lymphoma, Large B-Cell, Diffuse 1

Interventions

Cyclophosphamide 886Rituximab 864Vincristine 382Etoposide 381fludarabine 342Cytarabine 341Doxorubicin 340fludarabine phosphate 319Methotrexate 310Dexamethasone 283Prednisone 282Lenalidomide 245Filgrastim 228Melphalan 200Peripheral Blood Stem Cell Transplantation 184Radiotherapy 175Whole-Body Irradiation 172Busulfan 165Mycophenolic Acid 161venetoclax 158Bendamustine Hydrochloride 158Granulocyte Colony-Stimulating Factor 151Tacrolimus 145ibrutinib 144Bortezomib 138obinutuzumab 125Gemcitabine 113Cyclosporine 110Antilymphocyte Serum 103Carmustine 100

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × vatalanib × Lymphoid × Clear all
NCT00511043 2014-12-09

PTK787 in Refractory or Relapsed Diffuse Large Cell Lymphoma

Duke University

Phase 2 Terminated
20 enrolled
Lymphoid

Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡